Melittin ameliorates inflammation in mouse acute liver failure via inhibition of PKM2-mediated Warburg effect

Acta Pharmacol Sin. 2021 Aug;42(8):1256-1266. doi: 10.1038/s41401-020-00516-0. Epub 2020 Sep 16.

Abstract

Acute liver failure (ALF) is a fatal clinical syndrome with no special drug. Recent evidence shows that modulation of macrophage to inhibit inflammation may be a promising strategy for ALF treatment. In this study we investigated the potential therapeutic effects of melittin, a major peptide component of bee venom both in mice model of ALF and in LPS-stimulated macrophages in vitro, and elucidated the underlying mechanisms. ALF was induced in mice by intraperitoneal injection of D-galactosamine/LPS. Then the mice were treated with melittin (2, 4, and 8 mg/kg, ip). We showed that melittin treatment markedly improved mortality, attenuated severe symptoms and signs, and alleviated hepatic inflammation in D-galactosamine/LPS-induced ALF mice with the optimal dose being 4 mg/kg. In addition, melittin within the effective doses did not cause significant in vivo toxicity. In LPS-stimulated RAW264.7 macrophages, melittin (0.7 μM) exerted anti-oxidation and anti-inflammation effects. We showed that LPS stimulation promoted aerobic glycolysis of macrophages through increasing glycolytic rate, upregulated the levels of Warburg effect-related enzymes and metabolites including lactate, LDHA, LDH, and GLUT-1, and activated Akt/mTOR/PKM2/HIF-1α signaling. Melittin treatment suppressed M2 isoform of pyruvate kinase (PKM2), thus disrupted the Warburg effect to alleviate inflammation. Molecular docking analysis confirmed that melittin targeted PKM2. In LPS-stimulated RAW264.7 macrophages, knockdown of PKM2 caused similar anti-inflammation effects as melittin did. In D-galactosamine/LPS-induced ALF mice, melittin treatment markedly decreased the expression levels of PKM2 and HIF-1α in liver. This work demonstrates that melittin inhibits macrophage activation-mediated inflammation via inhibition of aerobic glycolysis by targeting PKM2, which highlights a novel strategy of using melittin for ALF treatment.

Keywords: Akt/mTOR/PKM2/HIF-1α signaling.; M2-type pyruvate kinase; Warburg effect; acute liver failure; glycolysis; inflammation; melittin.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / metabolism
  • Anti-Inflammatory Agents / therapeutic use*
  • Anti-Inflammatory Agents / toxicity
  • Antioxidants / metabolism
  • Antioxidants / therapeutic use*
  • Antioxidants / toxicity
  • Galactosamine
  • Glycolysis / drug effects*
  • Inflammation / drug therapy
  • Inflammation / etiology
  • Lipopolysaccharides
  • Liver Failure, Acute / chemically induced
  • Liver Failure, Acute / complications
  • Liver Failure, Acute / drug therapy*
  • Male
  • Melitten / metabolism
  • Melitten / therapeutic use*
  • Melitten / toxicity
  • Mice
  • Mice, Inbred C57BL
  • Molecular Docking Simulation
  • Protein Binding
  • Pyruvate Kinase / metabolism*
  • RAW 264.7 Cells

Substances

  • Anti-Inflammatory Agents
  • Antioxidants
  • Lipopolysaccharides
  • Melitten
  • Galactosamine
  • Pkm protein, mouse
  • Pyruvate Kinase